

Docket No.: 17728

FORM PTO-1595 (Modified)  
(Rev. 03-01)  
OMB No. 0651-0027 (exp. 5/31/2002)  
P08A/REV03

## RECORDATION FORM COVER SHEET

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

## PATENTS ONLY

Tab settings → → → ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copy thereof.

## 1. Name of conveying party(ies):

**Pfizer Italia S.r.l.**  
(formerly Pharmacia Italia S.p.A.)

Additional names(s) of conveying party(ies)

☐ Yes ☒ No

## 2. Name and address of receiving party(ies):

Name: **Nerviano Medical Sciences S.r.l.**Address: **Viale Pasteur, 10**

## 3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ OtherExecution Date: **March 30, 2006**City: **Nerviano, Milan** State/Prov.: \_\_\_\_\_Country: **Italy** ZIP: **20014**

Additional name(s) &amp; address(es)

☐ Yes ☒ No

## 4. Application number(s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

Patent Application No.

Filing date

B. Patent No.(s)

**6,906,199**

issued  
June 14, 2005

Additional numbers

☐ Yes ☒ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **Peter I. Bernstein**Registration No. **43,497**Address: **Scully, Scott, Murphy & Presser, P.C.****400 Garden City Plaza, Suite 300**City: **Garden City** State/Prov.: **New York**Country: **USA** ZIP: **11530**

## 6. Total number of applications and patents involved:

**1**7. Total fee (37 CFR 3.41):.....\$ **40.00**☐ Enclosed - Any excess or insufficiency should be credited or debited to deposit account☒ Authorized to be charged to deposit account

## 8. Deposit account number:

**19-1013/SSMP**

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

## 9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

**Peter I. Bernstein**

Name of Person Signing

Signature

**July 19, 2006**

Date

**25**

Total number of pages including cover sheet, attachments, and document:

Mail documents to be recorded with required cover sheet information to:  
Mail Stop Assignment Recordation Services  
Director of the United States Patent and Trademark Office  
P.O. Box 1450, Alexandria, VA 22313-1450

PATENT

REEL: 017957 FRAME: 0588

700276592

CH \$40.00 191013 6906199

## ASSIGNMENT

WHEREAS, PFIZER Italia S.r.l., is a registered company in Italy, having a place of business at Via Valbondione, 113, Rome, Italy 00188, (formerly PHARMACIA Italia S.p.A., a registered company of Italy having a place of business at Via Robert Koch, 1-2, Milan, Italy 1-20152) (hereinafter, "ASSIGNOR");

WHEREAS, the ASSIGNOR owns certain rights in and to certain patents, utility models and patent applications (whether provisional or otherwise), for the United States of America and other countries foreign thereto;

WHEREAS, NERVIANO MEDICAL SCIENCES S.r.l., a registered company of Italy, having a place of business at Viale Pasteur, 10, Nerviano (MI), Italy 20014 (hereinafter, "ASSIGNEE");

Now, therefore, for good and valuable consideration, receipt of which is acknowledged, the ASSIGNOR has agreed to assign and transfer and does hereby assign and transfer unto ASSIGNEE, its successors and assigns, all of the right, title and interest which ASSIGNOR owns in and to the patents, utility models, and patent applications (whether provisional or otherwise), listed in the Patent Schedule (attached hereto and made a part hereof) and in and to any division, continuation or continuation-in-part, of said applications, and in and to any and all Letters Patent and reissues and extensions thereof, of the United States of America and all countries foreign thereto (including the right to apply for Letters Patent in foreign countries in its own name and to claim any priority rights for such foreign applications to which such applications are entitled under international conventions, treaties or otherwise), which have been or may be granted on any of the foregoing to be held and enjoyed as fully and exclusively as they would have been by ASSIGNOR had this assignment and transfer not been made;

2

The ASSIGNOR does further agree to execute and deliver without further consideration any further applications, assignment and documents, and to perform such other acts as may be deemed necessary by said ASSIGNEE, its successors, assigns, and nominees, fully to secure its interest as aforesaid and to obtain or maintain Letters Patent in any and all countries;

And the undersigned do hereby authorize and request the U.S. Commissioner of Patents and Trademarks and the patent offices of all other countries of the world to issue any and all Letters Patents which may be granted upon any of the said applications, to the said ASSIGNEE, as the assignee of the entire interest herein.


In witness whereof, the undersigned have hereunto executed this document on the day and year set forth below.


ASSIGNOR

ASSIGNEE

PFIZER ITALIA S.r.l.  
(formerly PHARMACIA ITALIA S.p.A.)

NERVIANO MEDICAL SCIENCES S.r.l.

by:   
Name: Grover F. Fuller, Jr.  
Title: Attorney-In-Fact

by:   
Name: Dr. Francesco Colotta  
Title: VP, Oncology

Date: 15 MARCH 2006Date: 30 MARCH 2006Witness: Witness: 

**PATENT SCHEDULE**

<u>TITLE</u>	<u>COUNTRY</u>	<u>APPLN.NO/ PATENT NO.</u>	<u>NMS REF.</u>	<u>PFIZER REF.</u>
Method For Predicting the Sensitivity to Chemotherapy	Canada	2,459,194	PHA-00700	PC27137
Method For Predicting the Sensitivity to Chemotherapy	EPO	02779404.9	PHA-00700	PC27137
Method For Predicting the Sensitivity to Chemotherapy	Hong Kong	041 10169.0	PHA-00700	PC27137
Method For Predicting the Sensitivity to Chemotherapy	Japan	2003-532987	PHA-00700	PC27137
Method For Predicting the Sensitivity to Chemotherapy	U.S.	6,969,592	PHA-00700	PC27137A
Method For Predicting the Sensitivity to Chemotherapy	U.S.	10/487,932	PHA-00700	PC27137B
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Australia	2002352090	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Brazil	PI0215454-4	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Canada	2,472,008	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	China	02827674.4	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Colombia	04.063.496	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	EPO	02787763.8	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Hong Kong	05105503.4	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Hungary	P04 02639	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	India	1960/DELNP/04	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Indonesia	W00200401412	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Israel	162820	PHA-00777	PC27210

Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Japan	2003-556098	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Korea	2004-7010472	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Mexico	2004/006543	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	New Zealand	533854	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Norway	2004 3217	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Philippines	1-2004-500983	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Poland	P-371 179	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine	Romania	2004-00608	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Russian Federation	2004-123641	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Singapore	200404027-5	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	South Africa	2004/5290	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	U.S.	10/500,606	PHA-00777	PC27210A
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Tyrosine Kinase Inhibitors	Vietnam	1-2004-00727	PHA-00777	PC27210
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Australia	2003219102	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Brazil	PI 0308976-2	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Canada	2,481,005	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	China	O3809983.7	PHA-00937	PC27330

Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Colombia	04.098.266	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	EPO	03 714888.9	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Hong Kong	05 111365.9	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	India	2994/DELNP/04	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Indonesia	WO0 2004 02143	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Israel	164356	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Japan	2003-579805	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Korea	2004-7015602	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Mexico	2004/009542	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	New Zealand	535700	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Norway	20044709	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Philippines	1-2004-501568	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Poland	P-373998	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Russian Federation	2004131860	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Singapore	200405536-4	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	South Africa	2004/7948	PHA-00937	PC27330
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	U.S.	10/957,507	PHA-00937	PC27330A

Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy	Vietnam	1-2004-01137	PHA-00937	PC27330
Morpholinyl Anthracycline Derivatives	EPO	O 889 898	FC-FC775	PC28461
Morpholinyl Anthracycline Derivatives	Japan	505541/98	FC-FC775	PC28461
Process for Preparing Distamycin Derivatives	Albania	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Argentina	P010105477	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Armenia	O05399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Australia	2002-220696	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Austria	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Azerbaijan	O05399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Belarus	O05399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Belgium	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Brazil	PI 0115351-0	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Canada	2,427,177	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Chile	2001-2877	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	China	O1819386.2	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Colombia	O3-053205	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Cyprus	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Czech Republic	2003-1132	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Denmark	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Estonia	P2003 00204	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Eurasia	O05399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	EPO	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Finland	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	France	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Germany	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Greece	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Hong Kong	HK 1060732	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Hungary	P0302158	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	India	996/CHENP/03	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Indonesia	W002003 01041	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Ireland	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Israel	155385	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Italy	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Japan	2002-546517	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Kazakhstan	O05 399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Korea	2003-7007081	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Kyrgyz Republic	O05399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Latvia	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Lithuania	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Luxembourg	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Macedonia	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Malaysia	PI20015410	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Mexico	232492	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Moldova	O05399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Monaco	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Netherlands	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	New Zealand	525230	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Norway	20032297	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Pakistan	138016	PHA-00304	PC26788

PATENT

REEL: 017957 FRAME: 0594

Process for Preparing Distamycin Derivatives	Pakistan	1110/2001	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Peru	001178-2001	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Philippines	1-2003-500275	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Poland	P362179	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Portugal	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Romania	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Russian Federation	005399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Singapore	96465	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Slovakia	832-2003	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Slovenia	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	South Africa	2003/2771	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Spain	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Sweden	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Switzerland	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Taiwan	90128821	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Tajikistan	005399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Thailand	069957	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Turkey	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	Turkmenistan	005399	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	United Kingdom	1 347 958	PHA-00304	PC26788
Process for Preparing Distamycin Derivatives	U.S.	6,906,199	PHA-00304	PC26788A
Process for Preparing Distamycin Derivatives	Venezuela	2001-002481	PHA-00304	PC26788
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	ARIPO		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	OAPI	1200500329	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Algeria	050451	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Antigua and Barbuda		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Argentina	P04 01 01748	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Australia	2004240772	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Barbados	2001/1177	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Bosnia and Herzegovina	BAP 052273A	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Brazil	PI0410563-0	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Canada	2,526,578	PHA-01079	PC27464



Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Chile	2004-1173	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	China		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Colombia	O5.118.410	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Costa Rica		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Croatia	P20050967A	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Cuba	2005/0228	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Ecuador	SP-05-6194	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Egypt	749/2005	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Eurasia		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	EPO	O4741483.4	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Georgia		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Hong Kong		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Iceland	8132	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	India	5352/DELNP/2005	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Indonesia	W-00 2005 03092	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Israel	172046	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Japan		PHA-01079	PC27464

Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Korea	10-2005-7022355	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Malaysia	PI 20041795	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Mexico	PA/A/2005/012573	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Mongolia	3677	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	New Zealand	543661	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Nicaragua	2005/02021	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Norway	2005 5496	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Pakistan	367/2004	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Philippines	1-2005-502088	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Serbia and Montenegro	P-944/05	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Singapore	200507117-0	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	South Africa	2005/08486	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Sri Lanka	13892	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Taiwan	93112449	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Thailand	090552	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Trinidad and Tobago	TT/A/2005/00188	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Tunisia	SN05298	PHA-01079	PC27464

Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Ukraine		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	U.S.	10/557,565	PHA-01079	PC27464A
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Uzbekistan		PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Venezuela	2004-000815	PHA-01079	PC27464
Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use As Kinase Inhibitors	Vietnam	1-2005-01901	PHA-01079	PC27464
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Argentina	P01010243	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Australia	2001 260227	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Austria	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Belgium	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Brazil	PI 0110628-7	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Canada	2409664	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	China	01809203.9	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Colombia	02100806	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Cyprus	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Czech Republic	2002-3629	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Denmark	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Estonia	P2002-00605	PHA-00155	PC26650

Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Eurasia	2002-01184	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	EPO	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Finland	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	France	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Germany	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Greece	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Hong Kong	03106491.8	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Hungary	P0301882	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	India	2002/01975	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Indonesia	W-00200202525	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Ireland	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Israel	152388	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Italy	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Japan	2001-581798	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Korea	2002-7015026	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Luxembourg	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Mexico	231455	PHA-00155	PC26650

Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Monaco	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Netherlands	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	New Zealand	522234	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Norway	20025303	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Philippines	1-2001-01092	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Poland	P-365831	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Portugal	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Singapore	92505	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Slovakia	1 600-2002	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	South Africa	2002/8531	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Spain	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Sweden	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Switzerland	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Taiwan	90110601	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Turkey	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	United Kingdom	1 280 527	PHA-00155	PC26650
Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	U.S.	10/258,620	PHA-00155	PC26650A

Use of Acryloyl Substituted Distamycin Derivatives in the Treatment of Tumors Associated with High Levels of Glutathione	Venezuela	2001-000966	PHA-00155	PC26650
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Australia	2001-278463	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Brazil	PI 0111813-7	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Canada	2,411,172	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	China	O1811639.6	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Colombia	O3.003.253	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Czech Republic	2002-4155	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Estonia	P2002 00681	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Eurasia	2003-00060	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	EPO	O1956495.4	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Hong Kong	O3106770.0	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Hungary	P0301257	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	India	77/CHEMNP/03	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Indonesia	W-00200202883	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Israel	153177	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Japan	2002-503266	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase I and II Inhibitors	Korea	2002-7017440	PHA-00156	PC26651

Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	Mexico	PA/a/2002/012163	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	New Zealand	523000	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	Norway	2002-6078	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	Poland	P360297	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	Singapore	94255	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	Slovakia	1833-2002	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	South Africa	2002-9834	PHA-00156	PC26651
Pharmaceutical Compositions Comprising Acryloyl Distamycin Derivatives and Topoisomerase 1 and 11 Inhibitors	U.S.	10/297,915	PHA-00156	PC26651A
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Australia	2001 281867	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Brazil	PI 0111740-8	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Canada	2,410,160	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	China	01811477.6	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Colombia	03.003.259	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Czech Republic	2002-4106	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Estonia	P2002 00660	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Eurasia	2003 00061	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	EPO	01960355.4	PHA-00154	PC26649

Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Hong Kong	O3106772.8	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Hungary	P0301234	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	India	76/CHENP/03	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Indonesia	W00200300116	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Israel	1 52956	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Japan	2002-503267	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Korea	2002-7017565	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Mexico	PA/a/2002/012209	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	New Zealand	522999	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl	New Zealand	535236	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Norway	2002 6077	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Poland	P-365158	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Singapore	93445	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	Slovakia	1834-2002	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	South Africa	2002/9836	PHA-00154	PC26649
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Alkylating Agents	U.S.	10/311,995	PHA-00154	PC26649A
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Argentina	P970103377	FC-FC781	PC28466



Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Australia	724511	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Austria	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Belarus	001863	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Belgium	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Brazil	PI9710717-4	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Canada	2,260,060	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	China	97196737.7	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Denmark	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Eurasia	001863	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	EPO	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Finland	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	France	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Germany	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Greece	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Hong Kong	HK1020948	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Hungary	224635	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Ireland	0 915 845	FC-FC781	PC28466

Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Israel	127689	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Italy	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Japan	508428/98	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Kazakstan	001863	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Korea	408538	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Malaysia	PI97003389	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Mexico	213458	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Netherlands	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	New Zealand	334082	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Norway	301817	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Poland	P331344	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Portugal	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Russian Federation	001863	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	South Africa	97/6549	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Spain	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Sweden	0 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Switzerland	0 915 845	FC-FC781	PC28466

Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Taiwan	103772	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	Ukraine	61922	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	United Kingdom	O 915 845	FC-FC781	PC28466
Acryloyl Substituted Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor and Antiviral Agents	U.S.	6,482,920	FC-FC781	PC28466A
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Australia	2001 267553	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Brazil	PI 0111814-5	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Canada	2,412,054	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	China	O1811607.8	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Colombia	O3.003.265	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Czech Republic	2002-4107	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Estonia	P200200688	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Eurasia	2003 00059	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	EPO	O1945297.8	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Hong Kong	O3106774.6	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Hungary	P0301334	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	India	78/CHENP/2003	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Indonesia	W00200202879	PHA-00157	PC26652

Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Israel	153 178	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Japan	2002-503104	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Korea	2002-7017409	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Mexico	PA/a/2002/012165	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	New Zealand	523001	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	New Zealand	543318	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Norway	2002 6076	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Poland	P363696	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Singapore	94256	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	Slovakia	1829-2002	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	South Africa	2002/9835	PHA-00157	PC26652
Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives, Taxanes and/or Antimetabolites	U.S.	10/297,620	PHA-00157	PC26652A
Antitumor Therapy Comprising Distamycin Derivatives	Argentina	P010104621	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Armenia	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Australia	2002 221622	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Azerbaijan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Belarus	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Brazil	PI 0114389-1	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Canada	2,424,116	PHA-00299	PC26786

Antitumor Therapy Comprising Distamycin Derivatives	Chile	2001-2373	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	China	01816755.1	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Colombia	03-035193	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Czech Republic	2003-909	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Estonia	P2003 00129	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Eurasia	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	EPO	01986259.8	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Hong Kong	04103423.7	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Hungary	P0301247	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	India	637/CHENP/03	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Indonesia	W00200300848	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Israel	154755	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Japan	2002-532214	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Kazakstan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Republic of Korea	2003-7004710	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Kyrgyz Republic	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Malaysia	PI20014542	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Mexico	2003-002824	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Moldova	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Norway	20031410	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Pakistan	137884	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Pakistan	925/2001	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Philippines	1-2003-500110	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Poland	P-363926	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Russian Federation	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Singapore	98094	PHA-00299	PC26786

PATENT

REEL: 017957 FRAME: 0608

Antitumor Therapy Comprising Distamycin Derivatives	Slovakia	503-2003	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	South Africa	2003/3405	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Taiwan	90124050	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Tajikistan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Thailand	068610	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Turkmenistan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	U.S.	6,576,612	PHA-00299	PC26786A
Antitumor Therapy Comprising Distamycin Derivatives	U.S.	10/381,272	PHA-00299	PC26786B
Antitumor Therapy Comprising Distamycin Derivatives	Venezuela	2001-002076	PHA-00299	PC26786
Anthracycline Derivatives	Germany	19547958.0	FC-FC689	PC28402
Anthracycline Derivatives	Italy	1277073	FC-FC689	PC28402
Anthracycline Derivatives	Japan	335216/95	FC-FC689	PC28402
Anthracycline Derivatives	United Kingdom	2296495	FC-FC689	PC28402
Oxidized Sulfurated Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor Agents	EPO	1 100 778	FC-FC855	PC28524
Oxidized Sulfurated Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor Agents	Germany	1 100 778	FC-FC855	PC28524
Oxidized Sulfurated Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor Agents	Italy	1 100 778	FC-FC855	PC28524
Oxidized Sulfurated Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor Agents	Japan	2000-562349	FC-FC855	PC28524
Oxidized Sulfurated Distamycin Derivatives, Process for Preparing Them and Their Use as Antitumor Agents	United Kingdom	1 100 778	FC-FC855	PC28524
Sulfurated Distamycin Derivatives, Process for Preparing Them, and Their Use as Antitumor Agents	EPO	1 100 777	FC-FC854	PC28523
Sulfurated Distamycin Derivatives, Process for Preparing Them, and Their Use as Antitumor Agents	Germany	1 100 777	FC-FC854	PC28523
Sulfurated Distamycin Derivatives, Process for Preparing Them, and Their Use as Antitumor Agents	Italy	1 100 777	FC-FC854	PC28523
Sulfurated Distamycin Derivatives, Process for Preparing Them, and Their Use as Antitumor Agents	Japan	2000-562348	FC-FC854	PC28523
Sulfurated Distamycin Derivatives, Process for Preparing Them, and Their Use as Antitumor Agents	United Kingdom	1 100 777	FC-FC854	PC28523

13-Dihydro-3-(2-Alkoxy-4-Morpholinyl) Antrocyclines	Germany	4126475	FC-FC496	PC28302
13-Dihydro-3-(2-Alkoxy-4-Morpholinyl) Antrocyclines	Italy	1251158	FC-FC496	PC28302
13-Dihydro-3-(2-Alkoxy-4-Morpholinyl) Antrocyclines	Japan	3068258	FC-FC496	PC28302
13-Dihydro-3-(2-Alkoxy-4-Morpholinyl) Antrocyclines	United Kingdom	9019933.2	FC-FC496	PC28302
13-Dihydro-3-(2-Alkoxy-4-Morpholinyl) Antrocyclines	United Kingdom	2247885	FC-FC496	PC28302
Method for Treating Liver Cancer	EPO	04710040.9	PHA-01526	PC27899
Method for Treating Liver Cancer	Japan	2006-502019	PHA-01526	PC27899
Method for Treating Liver Cancer	Taiwan	93104565	PHA-01526	PC27899
Method for Treating Liver Cancer	Thailand	088819	PHA-01526	PC27899
Method for Treating Liver Cancer	U.S.	10/546,234	PHA-01526	PC27899A
Method for Optimizing Therapeutic Efficacy of Nemorubicin	EPO	03809274.8	PHA-00947	PC27339
Method for Optimizing Therapeutic Efficacy of Nemorubicin	Japan	2004-545825	PHA-00947	PC27339
Method for Optimizing Therapeutic Efficacy of Nemorubicin	U.S.	10/533,017	PHA-00947	PC27339A
Method for the Detection of Microorganisms in Pharmaceutical Products	EPO	03779871.7	PHA-1175	PC27559
"A Human Homologue of the DBF4/ASK1 Protein, Nucleic Acids, and Methods Related to the Same"	EPO	01943521.3	PHA-218	PC26712
"A Human Homologue of the DBF4/ASK1 Protein, Nucleic Acids, and Methods Related to the Same"	Japan	2002/510675	PHA-218	PC26712
"A Human Homologue of the DBF4/ASK1 Protein, Nucleic Acids, and Methods Related to the Same"	USA	10/311,401	PHA-218	PC26712B

-END LIST-